DBV Technologies S.A. last reported quarterly results on Oct 28, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $1.6 million (-42.9% year over year) and diluted EPS of -$0.14. It usually reports 16–30 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 29, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Friday. Based on how many days after a quarter ends the company has reported recently. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 16–30 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 28, 2026
28 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
2
-42.9%
|
-64
-94.3%
|
-0.14
+41.7%
|
|
Jul 16, 2026
16 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1
-53.3%
|
-50
-20.3%
|
-0.12
+61.3%
|
|
Apr 30, 2026
30 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
1
+12.5%
|
-48
-75.6%
|
-0.11
+57.7%
|
|
Oct 29, 2025
29 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
3
+161.2%
|
-33
-9.1%
|
-0.24
+25.0%
|
|
Jul 29, 2025
29 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
2
+29.2%
|
-42
-26.5%
|
-0.31
+8.8%
|
|
Apr 30, 2025
30 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
1
-43.1%
|
-27
+0.9%
|
-0.26
+7.1%
|
|
Oct 22, 2024
22 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
|
Jul 30, 2024
30 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- DBVT (Nasdaq), DBVTF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- France
- Headquarters
- Chatillon
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1613780
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.